On this page

HALOG

Halcinonide Topical · Solution

Prescription NDA TE AT RLD Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
HALOG
Generic name
Halcinonide Topical
Dosage form
Solution
Route
Topical
Marketing category
NDA · NDA
Labeler
Genus Lifesciences Inc.
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
2
Packages
3
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Halcinonide 1 mg/mL 310669 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Topical
Presentations
5

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
017823
Application type
NDA · New Drug Application
Approval date
May 4, 1977
Sponsor
SUN PHARM INDS INC
Products on application
1
Submissions recorded
23
Products approved under application 017823.
Product Trade name Form Strength Ingredient Status TE Flags
017823-001 HALOG SOLUTION HALCINONIDE Prescription AT RLD

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
Yes
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 017823.
Type No. Action Status Date Review
Supplement 24 Manufacturing (CMC) Approved March 18, 2020 N/A
Supplement 23 Labeling Approved September 29, 2004 Standard
Supplement 22 Manufacturing (CMC) Approved October 8, 1996 Standard
Supplement 21 Manufacturing (CMC) Approved June 23, 1992 Standard
Supplement 20 Manufacturing (CMC) Approved June 27, 1989 Standard
Supplement 19 Manufacturing (CMC) Approved March 2, 1988 Standard
Supplement 18 Manufacturing (CMC) Approved July 30, 1985 Standard
Supplement 17 Manufacturing (CMC) Approved January 22, 1985 Standard
Supplement 16 Manufacturing (CMC) Approved August 30, 1984 Standard
Supplement 15 Manufacturing (CMC) Approved May 31, 1984 Standard
Supplement 14 Labeling Approved January 21, 1983 —
Supplement 13 Manufacturing (CMC) Approved December 30, 1981 Standard
Supplement 11 Manufacturing (CMC) Approved August 12, 1980 Standard
Supplement 10 Manufacturing (CMC) Approved June 20, 1980 Standard
Supplement 5 Labeling Approved April 18, 1980 —
Supplement 9 Manufacturing (CMC) Approved February 13, 1980 Standard
Supplement 8 Manufacturing (CMC) Approved January 29, 1980 Standard
Supplement 7 Manufacturing (CMC) Approved April 18, 1979 Standard
Supplement 6 Manufacturing (CMC) Approved January 10, 1979 Standard
Supplement 4 Manufacturing (CMC) Approved May 12, 1978 Standard
Supplement 3 Manufacturing (CMC) Approved January 9, 1978 Standard
Supplement 1 Manufacturing (CMC) Approved August 24, 1977 Standard
Original application 1 Type 3 - New Dosage Form Approved May 4, 1977 Standard

Review documents

  • 0 · Supplement · May 15, 2024
  • 0 · Supplement · May 15, 2024
  • 0 · Supplement · October 4, 2004
  • 0 · Supplement · October 4, 2004

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251105). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251105 HUMAN PRESCRIPTION DRUG · 20060706

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply HALOG SOLUTION (Halcinonide Topical Solution, USP) 0.1% to the affected area two to three times daily. Occlusive Dressing Technique Occlusive dressings may be used for the management of psoriasis or other recalcitrant conditions. Apply the solution to the lesion, cover with a pliable nonporous film, and seal the edges. If needed, additional moisture may be provided by covering the lesion with a dampened clean cotton cloth before the nonporous film is applied or by briefly wetting the affected area with water immediately prior to applying the medication. The frequency of changing dressings is best determined on an individual basis. It may be convenient to apply Halcinonide Topical Solution, USP 0.1% under an occlusive dressing in the evening and to remove the dressing in the morning (i.e., 12-hour occlusion). When utilizing the 12-hour occlusion regimen, additional solution should be applied, without occlusion, during the day. Reapplication is essential at each dressing change. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings (reactions are listed in an approximate decreasing order of occurrence): burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.

Description

openFDA Drug Labeling

DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. The steroids in this class include halcinonide. Halcinonide is designated chemically as 21-Chloro-9-fluoro-11β,16α, 17-trihydroxypregn-4-ene-3,20-dione cyclic 16,17-acetal with acetone. Graphic formula: C 24 H 32 ClFO 5 , MW 454.96, CAS-3093-35-4 Each mL of 0.1% HALOG SOLUTION (Halcinonide Topical Solution, USP) contains 1 mg halcinonide, edetate disodium, polyethylene glycol 300, and purified water with butylated hydroxytoluene as an antioxidant. halcinonide solution chemical structure

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS: General ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED HALOG® SOLUTION (Halcinonide Topical Solution, USP) 0.1% is supplied in plastic squeeze bottles containing 120 mL (NDC 64950-127-12) of solution. Storage Store at room temperature; avoid freezing and temperatures above 104° F. To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Distributed by: Genus Lifesciences Inc. Allentown, PA 18102 Revised: May 2025 5261181 50

Adverse event reports

Source: openFDA FAERS
193
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HALCINONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
0003-0249-15 0003-0249 E.R. Squibb & Sons, L.L.C. 20 mL in 1 BOTTLE, PLASTIC (0003-0249-15) January 1, 2009
0003-0249-20 0003-0249 E.R. Squibb & Sons, L.L.C. 60 mL in 1 BOTTLE, PLASTIC (0003-0249-20) January 1, 2009
64950-127-12 64950-127 Genus Lifesciences Inc. 1 BOTTLE, PLASTIC in 1 CARTON (64950-127-12) / 120 mL in 1 BOTTLE, PLASTIC November 17, 2025
0003-0249 0003-0249 E.R. Squibb & Sons, L.L.C. — January 1, 2009
64950-127 64950-127 Genus Lifesciences Inc. — November 17, 2025

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.